← All trials
NCT04300309
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 25, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 30, 2022
- First posted
- Mar 9, 2020
- Last posted
- Mar 9, 2020
- Enrollment
- 44
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NovartisLead sponsor
- University of CalabarOverall official - principal investigator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
- Groupement de Recherche Action en Santé (GRAS), Ouagadougou, Burkina FasoCollaborator
- Groupement de Recherche Action en Santé (GRAS), Ouagadougou, Burkina FasoOverall official - principal investigator
- Hôpital Général de Référence St Luc, Kisantu, DR CongoOverall official - principal investigator
- Clinical Research Unit NanoroCollaborator
- Medicines for Malaria VentureCollaborator
- University of the Sciences, Techniques and Technologies of BamakoOverall official - principal investigator
- Clinical Research Unit NanoroOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.